Following the experiment, the results reported a reduction in weight and excess fat
Column 4-Estimated CY 2026 Percent Change reflects the percent differences between the estimated ASC payment for CY 2025 and the estimated payment for CY 2026 based on the final update
Scientific References (External Links) Drug Testing and Analysis: Detection and in vitro metabolism of AOD9604 View Study Endocrinology: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice View Study Hormone Research: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone View Study Current Opinion in Investigational Drugs: AOD-9604 Metabolic View Study
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
Although, rare, but it can also cause adverse effects on many organs including heart, lungs, muscles, skin and nerves too
This parenteral preparation is unlikely to pose a threat of fluid overload except possibly in very small infants
